ReviewIn vivo (Athens, Greece)
Resumption of Immune Checkpoint Inhibitor Therapy Following Immune-related Adverse Events.
Review in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum Zinc Levels and Skin-related Adverse Events During Systemic Therapy for Renal Cell Carcinoma.In vivo (Athens, Greece)Observational
- Onset and Outcomes of Immune-related Adverse Events in Genitourinary Cancer Treated With Immune Checkpoint Inhibitors.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-related adverse events (irAEs) are excessive immune responses resembling autoimmune diseases, induced by immune checkpoint inhibitors (ICIs), and can affect organs throughout the body. In contrast to AEs associated with conventional cytotoxic anticancer agents, irAEs may persist or recur after treatment discontinuation. The risk of irAEs recurrence is thought to vary depending on the type and severity of the initial irAE, while the response rate depends on the type and sequence of ICIs re-administered. Therefore, the decision to resume ICI therapy depends on the type and severity of prior irAEs, as well as the anticipated benefits and risks of resumption. This review focuses on the risks and benefits of resuming ICI therapy after each irAE and summarizes the procedure for its resumption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.